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Abstract: Cyanobacterial toxins, particularly microcystins (MCs) and cylindrospermopsin (CYN),
are responsible for toxic effects in humans and wildlife. In order to counteract or prevent their
toxicity, various strategies have been followed, such as the potential application of chemoprotectants.
A review of the main substances evaluated for this aim, as well as the doses and their influence
on cyanotoxin-induced toxicity, has been performed. A search of the literature shows that research
on MCs is much more abundant than research on CYN. Among chemoprotectants, antioxidant
compounds are the most extensively studied, probably because it is well known that oxidative stress
is one of the toxic mechanisms common to both toxins. In this group, vitamin E seems to have the
strongest protectant effect for both cyanotoxins. Transport inhibitors have also been studied in the
case of MCs, as CYN cellular uptake is not yet fully elucidated. Further research is needed because
systematic studies are lacking. Moreover, more realistic exposure scenarios, including cyanotoxin
mixtures and the concomitant use of chemoprotectants, should be considered.
Keywords: microcystins; cylindrospermopsin; chemoprotection; transport inhibitors; antioxidant substances
1. Introduction
Cyanotoxins are produced by various cyanobacteria species and are responsible for intoxications
in both humans and wildlife. There is increasing interest in studies of cyanotoxins owing to their
worldwide distribution and occurrence, and potential toxic blooms are more and more frequently
reported. Moreover, not only can cyanotoxins be present in surface waters but also they can be
accumulated in aquatic organisms and plants, some of them used as food sources [1]. Thus these toxins
are of concern not only for environmental agencies but also for the European Food Safety Authority
(EFSA) [2]. The most investigated group among cyanotoxins is that of microcystins (MCs), particularly
MC-LR, but cylindrospermopsin (CYN) is gaining considerable importance.
The toxic effects induced by both types of toxin depend on their toxicokinetic and toxicodynamic
characteristics. MCs are classified as hepatotoxins, whereas CYN is considered a cytotoxin.
Toxic mechanisms reported for MCs and CYN are cyanotoxin-specific, although they also show some
similarities. The resulting toxic effects are widely described in the scientific literature. These toxins
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have been shown to induce histopathological effects [3–5], genotoxicity [6,7], neurotoxicity [8,9],
developmental toxicity [10–12], reproductive toxicity [13,14], etc. In this regard, Buratti et al. [15]
recently reviewed the most relevant aspects (producing organisms, biosynthesis/genetics and
occurrence, toxicological profile) of various cyanotoxins, including MCs and CYN.
In order to prevent or counteract the toxic effects induced by MCs and CYN, various
chemicals have been studied in a number of experimental models, in vitro and in vivo.
These chemoprotectants include inhibitors of toxin-specific transporters (rifampicin, naringin, etc.),
antioxidant substances (vitamin E, vitamin C, N-acetylcysteine, L-carnitine, selenium, silymarin, lipoic
acid, epigallocatechin-3-gallate, etc.), tumor necrosis factor-α antiserum, and anti-inflammatory agents,
among others. Most of the reports in the scientific literature are focused on antioxidant substances that
have been shown to act on oxidative stress biomarkers and histopathological damage.
The aim of this work is to synthesize, update, and compare the available information on the use
of chemoprotectants to prevent/counteract the toxicity induced by MCs and CYN. These data would
be useful in the decision-making process after the occurrence of cyanobacterial toxicosis and to prevent
its appearance.
2. Microcystins
Microcystins are cyclic peptides consisting of seven amino acids, including several
D-amino acids and two unusual amino acids, N-methyldehydroalanine (Mdha) and
3-amino-9-methoxy-2-6,8-trimethyl-10-phenyldeca-4,6-dienoic acid (Adda) [16]. More than
100 MC variants are described, MC-LR being the most studied congener, owing to its ubiquity,
abundance, and toxicity [15]. The cellular uptake of these toxins [17] is mediated by the organic anion
transport system (OATP).
MCs have been related to human and wildlife intoxications, with a fatal outcome in some
cases. However, the true incidence is not known, although it is increasing, according to Wood [18].
Severe liver damage, intrahepatic hemorrhage, hemodynamic shock, and heart failure are the most
frequent negative effects related to these cyanotoxins. Other organs affected are the kidneys, lungs,
and intestines [16]. Moreover, neurotoxic effects have been reported and other organs, such as the
thyroid seem to be affected [15].
With regard to the toxic mechanisms of MCs, they are mainly associated with inhibition of
protein phosphatases 1 and 2A (PP1 and PP2A) and disruption of the cellular phosphorylation
balance [19–21], affecting numerous signaling pathways. MCs can also induce oxidative stress by
two primary pathways [22]. First, by glutathione (GSH) depletion, leading to oxidative damage and
cell death. In fact, it is known that conjugation with GSH is the first step in the detoxication of this
cyanobacterial toxin [23]. Second, increasing reactive oxygen species (ROS) production by disrupting
the mitochondrial electron transport chain, leading to mitochondrial permeability transition and
release of apoptotic factors, finally resulting in apoptosis [24]. Moreover, ROS can lead to increased
lipid peroxidation (LPO), DNA damage, DNA-protein crosslink, and alteration of the antioxidant
defense system [25,26].
With regard to the apoptosis referred to above, in addition to the mitochondrial damage already
mentioned, MCs could also affect the endoplasmic reticulum (ER). MC-LR exposure causes ER
distention and stress [24]. Moreover, MC-LR may produce toxic effects by causing cytoskeletal
disruption. It induces the rearrangement or collapse of the three components of the cytoskeleton:
microfilaments, microtubules, and intermediate filaments [24].
Finally, PP1/2A inhibition and oxidative stress exerted by MCs cause differential
expression/activity of transcriptional factors and proteins involved in the pathways of cellular
differentiation, proliferation, and tumor promotion [27]. MC-induced DNA damage is also involved in
carcinogenicity, with MC-LR classified as a possible human carcinogen (Group 2B) by the International
Agency for Research on Cancer [28]. Taking into account the scientific literature, there is a lack of
studies carried out on other MC congeners different from MC-LR, such as MC-RR or MC-YR [29,30].
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As has been shown, MCs use various pathways to exert their toxic effects. Therefore, the use of
substances that act on the same pathways or that avoid cellular uptake of the toxin could potentially
prevent or ameliorate the toxicity observed.
In view of the rapid and severe damage to the liver caused by MCs, therapy would probably have
little or no value, and effective prophylaxis is critical. Despite the potential human hazards associated
with MCs, there is no data available on the potential of protective strategies to treat human poisoning.
Also, the development of effective chemoprotectants against these toxins in experimental models is
still scarce [31,32]. Various chemically unrelated compounds have shown in vivo protection against
MC toxicity in mice [33]. Among the pioneers’ works, Adams et al. [34] investigated chemicals known
to affect macrophage function as potential prophylactic agents. Hermansky et al. [35,36] examined
the effectiveness of several compounds, including antioxidants, enzyme inducers, calcium channel
blockers, free-radical scavengers, and hepatic activity modulators, in preventing the toxicity of a
lethal dose of MC-LR (100 µg/kg). Enzyme induction by phenobarbital caused partial protection, and
limited protection from the lethality of MC-LR was observed in calcium channel inhibitors. This lack of
effectiveness of calcium blockers might be related to a possible involvement of calcium in the toxicity
of MC-LR; the toxin may cause membrane disruptions at sites that are not directly associated with
calcium channels [36]. Treatment with GSH or the monoethyl ester of glutathione (GMME) i.p. 2 h
before, with, and 2 h after MC-LR provided significant protection from lethality. A physical inhibition
of absorption may be responsible for the protective effects; both compounds may react with MC-LR
in the peritoneal cavity, preventing absorption of sufficient toxin to produce toxicity [32]. Finally, an
increased hepatic GSH content of the liver may offer protection from the oxidative stress induced
by MC-LR. Kaya et al. [37] reviewed neutralization of the toxicosis induced by MCs, and classified
the agents as follows: (a) Bile acid transport inhibitors; (b) Antioxidants; (c) Tumor necrosis factor-α
(TNF-α) antiserum; (d) Anti-inflammatory agents.
In this review, Table 1 [31–33,35,36,38–65] shows the various chemoprotectants found in the
scientific literature that have been studied with this application, with an indication of the experimental
model used (mainly in vivo models), doses or concentration of MCs or the cyanobacterial extract
containing MCs which induced damage or intoxication, and the doses of chemoprotectant assayed
with the most relevant effects observed against MCs. The majority of the studies have been carried out
in mammals (mice), although recently more investigations have been performed on aquatic organisms.
In general, analysis of the data indicates that the information available is still limited. Therefore,
more laboratory experiments are needed, particularly in rats by oral route, in order to obtain a better
correlation with human health.
2.1. Transporter Inhibitors
The prerequisite for the toxic effects of MCs appears to be their uptake into cells [66]. In this regard,
the uptake of MCs into hepatic and neuronal cells has been widely characterized, partly explaining
the fact that the target organs of MCs are mainly liver and brain [67]. The first insights into MC
transport were observed in rat hepatocytes, where basolateral uptake of MCs was inhibited by cholate,
taurocholate, and bromosulfophthalein [45,67]. These compounds are substrates of the organic anion
transporting polypeptide (OATP) superfamily of membrane transporters [68,69]. OATPs are expressed
in the brain (blood–brain barrier, choroid plexus) as well as in the liver [66]. However, members of
the multispecific OATP family can be detected in nearly all tissues of humans, rodents, and other
animals [70]. The human OATP family is composed of 11 members that share a similar structure [71].
Three of these transporters have shown the ability to transport MCs: the hepatocyte-enriched OATP
1B1 and OATP 1B3 transporters, and the ubiquitous OATP 1A2, primarily expressed at the blood–brain
barrier [66,72,73]. Inhibition of these transporters has been evidenced in studies on the mechanism of
entrance of MCs into cells. The possibility of using inhibitors of MC transport to avoid its toxic effects
has been studied for more than 20 years.
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Table 1. Protective effects of different chemoprotectants on microcystin (MC)-induced toxicity.
Chemoprotectant ExperimentalModel Used
Doses/Concentration
of MCs
Dose of
Chemoprotectant Effect of Chemoprotectant References
N-acetylcysteine (NAC) Primary rat hepatocytes
120 µg/mL from a
microcystic
cyanobacteria extract
NAC: 10 mM Cells pretreated for 6 h showed reduced cytotoxicity and enhancedthe intracellular GSH level. [37]
NAC
Mouse 100 µg/kg
NAC: 15 mg/kg
NAC: 1 h pretreatment extended survival time; at 3 and 24 h
pretreatment 25% of the animals survived. Coadministration was not
effective.
[33]
L-cysteine (Cys) Amifostine: 226 mg/kg L-Cys: only at 24 h pretreatment extended survival time.
Amifostine L-Cys: 280 mg/kg Amifostine: No protection though a slight increase in survival timewas observed.
Glutathione (GSH) GSH: 2000 mg/kg GSH: only at 3 h pretreatment protected 25% of the mice, andcoadministration protected 50%.
NAC Tilapia (Oreochromisniloticus) 120 µg MC-LR/fish
20, 44, or 96.8 mg
NAC/fish /day,
pretreatment during
7 days
NAC reduced hepatic and renal oxidative stress induced by MCs,
recovering LPO, GSH levels, and increased antioxidant enzyme
activities, mainly by the lower dose. The highest dose induced
alterations in SOD, GPx, and GR activities.
[39]
NAC Tilapia (O. niloticus) 120 µg MC-LR/fish
20, 44, or 96.8 mg
NAC/fish /day,
pretreatment during
7 days
Prevention of histopathological changes in a dose-dependent way
(20–44 mg/NAC/fish/day) in the liver, kidney, heart,
gastrointestinal tract, and gills
[40]
NAC CHO cells 0, 2.5, 5, and 10 µgMC-LR/mL 0, 1, and 5 nmol/L
NAC has a protective effect by increasing cell viability, decreasing
ROS, elevating MMP, and reducing apoptosis index. [41]
Cys
Mouse 10 mM MC-LR
L-Cys: 10 mM MC-LR in Cys solution did not cause acute liver toxicity. However,
MC-LR in GSH solution showed weaker acute toxicity of MC-LR
than intact MC-LR.
[42]
GSH GSH: 10 mM
Cyclosporin A (CyA)
Mouse 100 µg/kg
CyA: 10 mg/kg
CyA: Pretreatment for 1 and 3 h showed 100% protection and
extended survival time. Coadministration gave 100% protection, and
post-treatment could not prevent lethality.
[33]
Naringin Naringin: 50 mg/kg Naringin: protected 25% of the animals after 1 h pretreatment, and at3 and 24 h pretreatment only survival time was marginally extended.
Rifampicin Rifampicin: 25mg/kg
Rifampicin: pretreatment 1 h completely protected all the mice.
Coadministration gave 100% protection. Post-administration 15 and
30 min 75% of the animals were protected.
Silymarin Silymarin: 400 mg/kg Silymarin: protected 75% after 1 h pretreatment and 100% protectionafter 3 and 24 h.
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Table 1. Cont.
Chemoprotectant ExperimentalModel Used
Doses/Concentration
of MCs
Dose of
Chemoprotectant Effect of Chemoprotectant References
CyA Mouse 100 µg/kg (MC-LR) i.p. 100 mg/kg Prevented lethality when given 0.5–3 h prior to MC-LR [35]
CyA Mouse 1.7–1.8 × LD50 MC(MC-LR, -RR, -LY, -LA) 0.2 mg/mouse
Prevented 90% lethality when given up to 1 min after MC-LR
administration. After 5 min no protection was observed. [43]
Cytochalasins (Cyt)
Primary cultures of rat
hepatocytes
1 µg/mL (MC-LR)
Cyt: 10 µM
Cyt and bile acids showed negative effects when administered alone
to cells. Higher protective effect of Rif was observed in hepatocytes
treated with lower concentrations than bile acids.
[44]
Rifampicin (Rif) Rif: 2 µM
Bile acids (cholic acid
and deocycholate) Bile acids: 0.1 mM
Trypan blue (TB) TB: 20 µM
Trypan red (TR) TR: 20 µM
CyA
Isolated rat hepatocytes 320 mM MC-YM
CyA: 5 µM
Decreased accumulation of MC-YM after 30 min of exposure was
observed when cells were pretreated for 1 min with chemoprotectant.
The reductions observed were 37% for CyA, 26% for Rif, 30% for TB,
and 66% for TR.
[45]
Rifampicin Rif: 50 µM
TB TB: 20 µM
TR TR: 20 µM
CyA
Mouse 100 µg/kg MC-LR
CyA: 10 mg/kg Pretreatment with all substances provided 100% protection against
lethality. However, some of the toxic effects of MC-LR (such as GSH
depletion, lipid peroxidation and protein phosphatase inhibition)
were observed in surviving animals up to 7 days after exposure but
normalized after 14 days.
[46]Rifampicin Rif: 25 mg/kg
Silymarin Sy: 400 mg/kg
Epigallocatechin-3-gallate HUVECs 40 µM MC-LR 0–50 µM
EGCG reversed oxidant effects by reducing ROS and increasing SOD
and GSH levels, and reduced NF-kB in cells. Moreover, it suppressed
MC-LR-induced expression of ICAM-1 and VCAM-1, associated
with inflammatory processes.
[47]
Flavonoids: quercetin,
silybin, morin Mouse
0.75 LD50 MC-LR:
57.5 µg/kg
Quercetin: 200 mg/kg
Silybin: 400 mg/kg
Morin: 400 mg/kg
The levels of the hepatic enzymes ALT, AST, and LDH were reversed
to control at 3 days post-exposure.
At 3 days, the PPAse activity was reversed to control values in all the
flavonoid-treated groups
[48]
D-glucose
Mouse 100 µg/kg
D-glucose: 2000 mg/kg D-glucose pretreatment increased survival time, but showed no
protection from lethality. Mannitol and DHA had no protective effect
at all the pretreatment time points, although mannitol extended
survival time. Trolox ® at 24 h pretreatment protected 25% of the
animals. Only Trolox coadministered with MC-LR significantly
extended survival time but it could not prevent lethality.
[33]
Mannitol Mannitol: 2000 mg/kg
Dihydroxy-acetone Dihydroxy-acetone:50 mg/kg
Trolox Trolox: 10 mg/kg
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Table 1. Cont.
Chemoprotectant ExperimentalModel Used
Doses/Concentration
of MCs
Dose of
Chemoprotectant Effect of Chemoprotectant References
Lipoic acid
Common carp
(Cyprinus carpio,
Cyprinidae)
50 µg MC/kg i.p. 40 mg/kg i.p. Co-exposure led to an increase in GST activity in brain and revertedGST inhibition in liver. [49]
Lipopolysaccharide
Artemia salina
Daphnia magna,
Daphnia galeata
A. salina: 2 µg/mL MC-LR
D. magna: 1.26 µg/mL
MC-LR
D. galeata: 0.003 µg/mL
MC-LR
2 ng/mL
Pre-incubation and simultaneous addition of LPS and MC-LR
protected from lethal toxicity of MC-LR. The protective effect of LPS
is mediated by detoxication enzyme pathways.
[50]
Naringin Isolated rat hepatocytes 0.3–1 µM MC-LR 100 µM
Naringin prevented phosphorylation and disruption of the
cytoskeleton caused by MC-LR. Moreover, dose-dependent
apoptosis induced by MC-LR was suppressed by naringin.
[51]
Naringin Freshwater snail(Sinotaia histrica) 13.7 mg/g D.W. MC-LR 1–10 mM
One single exposure to 1 mM naringin prevented 60% of MC-LR
uptake in hepatopancreas. The uptake prevention rate was 100%
when snails were continuously treated with 10 mM naringin for
8 days.
[52]
Naringin HEK293-OATP1B3 cells 1–200 µM MC-LR 5-500 µM
Cytotoxicity of MC-LR was attenuated by naringin in a
dose-dependent manner as the uptake of MC-LR into
HEK293-OATP1B3 cells was inhibited by naringin.
[53]
Nostocyclopeptide-M1
(Ncp-1M)
Isolated rat hepatocytes,
HEK293-OATP1B3,
OATP1B1, OATP2B1
50 nM [125I]-MC-YR 10-20 µM
Ncp-1M inhibits the human MC-carrying transporters OATP1B1 and
OATP1B3, blocking MC uptake. [54]
Polyphenols
(Green tea, GTP) Mouse
10 µg/kg/day
(MC-LR) i.p.
50, 100 and
200 µg/kg/day
GTP protected by elevating in serum antioxidant activities (GSH and
SOD), reducing MDA level, inhibiting ROS, hepatocellular apoptosis,
and up-regulating Bcl-2 protein expression. Multifocal liver cell
degeneration and zonal coagulative necrosis were ameliorated.
[31]
Se (Sodium selenite) Mice
75 ìg /kg MC-LR, i.p.
(1 dose) sacrifice at 24 h
1.5 ìg /mouse/day, i.p.
(2 weeks prior to MC-LR)
Partial recovery of histopathological alterations in liver. Increase in
GST and GPx enzymatic activities.
[55]
62 ìg /kg MC-LR, i.p.
(10 doses) sacrifice at 72 h 1.5 ìg /mouse/day, i.p.(6 weeks prior to MC-LR)
Recovery of body weight in liver. Partial recovery of ALT levels and
glycogen (mg/g). Recovery of TBA values and GST levels. GPx
activity increase.
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Table 1. Cont.
Chemoprotectant ExperimentalModel Used
Doses/Concentration
of MCs
Dose of
Chemoprotectant Effect of Chemoprotectant References
Se (sodium selenite) Tilapia (O. niloticus)
Cyanobacterial cells
containing 120 µg
MC-LR/fish, 24 h
Pretreatment with 1.5, 3.0,
6.0 µg Se/g diet during
7 days
Se protection depended on the dose and the biomarker considered.
The highest dose of Se could affect some oxidative stress biomarkers.
The highest dose ameliorated the histopathological changes in the
liver, kidney, heart, and GI tract of fish.
[56]
κ-Selenocarrageenan
(Se-Car) BALB/c mice 50 µg/kg MC-LR i.p. 90 ppb
Se-Car reduced lipid and protein peroxidation induced by MC-LR.
Activities of GST and CAT were reduced and induced up-regulation
of SOD. It could also abate the toxicity through ER
function restoration.
[32]
Sulforaphane (SFN)
HepG2
BRL-3A
NIH 3 T3
10 µM of MC-LR 10 µM Protective response was mediated though Nrf2 pathway in vitro. [57]
SFN BALB/c mice 40 and 50 µg/kg MC-LRafter 8 h 5 µmol
SFN activated Nrf2 pathway in vivo and the protection included
activities of anti-cytochrome P450 induction, anti-oxidation,
anti-inflammation, and anti-apoptosis.
[58]
Vitamin E Mice 100 ìg /kg MC-LR, i.p. 86, 170, or 340 U i.p. 48 hprior to MC-LR
Prevention of death in 50% of the animals (up to 24 h) (with 170 or
340 U). Prevention of the serum LDH levels increase induced by MC
(with 340 U).
[36]
Vitamin E
(α- tocopherol acetate) Mice
100 µg/ kg MC-LR
extract, i.p. (7 doses)
100 µg/ kg MC-LR
extract, i.p. (1 dose)
8.33 or 33.3
UI/mouse/day
for 4 weeks
33.3 or 66.6
mg/mouse/day
for 2 weeks
Partial recovery of LPO, ALT, and GST parameters compared to the
control levels by reduction of LPO and ALT levels, and GST
increased compared to toxin-treated control group (with 33.3 mg)
in liver.
Reduction of liver damage (with 33.3 and 66.6 mg). Increased time to
death (with 66.6 mg)
[59]
Vitamin E
Estuarine crab
(Chasmagnathus
granulatus)
1.21 µg/kg/day MC-LR,
oral injection, sacrifice on
days 2 and 7
600 mg/kg bw/day
(41 days)
CAT activity decreased in gills. Recovery of GST activity compared
to the control levels.
Increase of nonproteic sulfhydryl groups.
[60]
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Table 1. Cont.
Chemoprotectant ExperimentalModel Used
Doses/Concentration
of MCs
Dose of
Chemoprotectant Effect of Chemoprotectant References
Vitamin E Tilapia (O. niloticus)
Cyanobacterial cells
containing 120 µg
MC-LR/fish, commercial
diet, 24 h
Pretreatment with 200 or
700 mg vitamin E/kg diet
during 7 days
Vitamin E-pretreated fish showed no alteration in LPO levels, and
oxidative enzymatic activities were improved. The highest dose
employed gave the greater protective effects.
[61]
Vitamin E Tilapia (O. niloticus)
Cyanobacterial cells
containing 120 µg
MC-LR/fish, with the diet.
Fish were sacrificed at 24,
48, or 72 h
Pretreatment with 200 or
700 mg vit E/kg diet
during 7 days
The oxidative stress biomarkers were ameliorated, and the higher
protection was observed 24 h post toxin exposure. Histopathological
lesions were more evidently recovered after 72 h.
[62]
Vitamin E
Vitamin C
Melatonin
Mice 75 ìg /kg MC-LR, i.p.(1 dose) sacrifice at 24 h
Vitamin E: 36.2 µM
Vitamin C: 30.4 µM
Melatonin: 0.55 µM
per mouse/day, for
2 weeks
Recovery of ALT levels: Melatonin > Vitamin E > Vitamin C.
Inhibition of 8-OH-dG formation in a dose-dependent manner:
Melatonin > Vitamin C ≈ Vitamin E.
[63]
Vitamin E
Vitamin C Mice
60 µg/kg MC-LR, i.p.,
sacrifice at 12 h
200 and 250 mg/kg
bw/day (3 days)
Decrease in ROS and MDA levels. Partial recovery of ALT and AST
levels compared to the control levels by reduction of both parameters
in liver. Protection against apoptosis and chromatin condensation
produced by MC-LR. Prevented decrease in membrane potential.
Recovery of Bax and Bid expression up to the control levels in liver.
[64]
Vitamin E
Trolox
Artemia franciscana
Nauplii
MC-LR (40 µg/mL) and
Microcystis aeruginosa
extract
(CE, 10 mg dw/mL)
100 µg/mL antioxidant
pretreatment
(4 h exposure)
Both antioxidant pretreatments reduced mortality of approximately
50% at 9 h post-exposure against MC-LR, but offered little to no
protection from cyanobacterial extract.
[65]
Abbreviations: ALT: Alanine amino transferase; AST: Aspartate amino transaminase; BRL-3A: Rat hepatocyte cell line; CHO: Chinese hamster ovary cells; GI: gastrointestinal;
HEK293-OATP1B3 (OATP1B1, OATP2B1) cells: human embryonic kidney cells transfected with SLCO1B3 (SLCO1B1, SLCO2B1); HepG2: Human hepatocellular liver carcinoma cell line;
HUVECs: Human umbilical vein endothelial cells; LDH: Lactate dehydrogenase; [125I]-MC-YR: MC-YR radiolabeled with 125I; MDA: malonyl dialdehyde; MMP: Mitochondrial membrane
potential; NIH 3 T3: Mouse embryonic fibroblast cell line; Nrf2: nuclear factor erythroid 2-related factor; 8-OH-dG: 8-hydroxydeoxyguanosine; ROS: reactive oxygen species.
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The first experiments dealing with the use of chemoprotectants were performed in vivo to observe
the prevention of death in mice exposed to MCs previously treated with cyclosporin A (CyA) [35,43].
The authors showed the importance of the time of pretreatment with this substance to avoid the
lethality of MCs at doses that produce 100% death of exposed mice. However, even if the protective
role of CyA could be related to the adequate prevention of MCs uptake into the hepatocyte, this was not
confirmed experimentally [35]. Furthermore, Stoner et al. [43] suggested that MCs and CyA may share
some unidentified membrane transport and cytosol effector mechanisms in proximal MCs target cells.
Later, Runnegar et al. [45] concluded that inhibition of MCs uptake by hepatocytes was the most likely
mechanism of chemoprotection for MCs in vivo toxicity for CyA as well as for other substances, such
as rifampicin, trypan blue, and trypan red. They stated that, although the chemoprotectants studied
were different chemically and in biological action, their protective effect must be either a common
interaction with the carriers for MCs in the hepatocyte or prevention of MCs binding and uptake
by the carrier. However, they were not able to gain insight into the possible transporter involved,
despite having used bile acids in the experiment. In this regard, hepatocellular uptake of MC-LR was
blocked by antamanide, bromosulfophthalein, rifampicin, and bile salts (cholate and taurocholate)
in freshly isolated rat hepatocytes, showing that the uptake of MC-LR was through the multispecific
transport system for the bile acids [67]. Similarly, Thomson and Pace [44] explained that the protective
effect of several substances (rifampicin, cytochalasin, bile acids, trypan blue, and trypan red) was
related to their implication in MCs uptake in the hepatocyte, highlighting the bile acid transport
system. They concluded that rifampicin was the best candidate to be used as a therapeutic drug
against MCs, being more effective at preventing MCs uptake at a lower concentration than bile acids in
this in vitro model. This protective finding was also observed in vivo in mouse pretreated with CyA,
rifampicin, and silymarin [33]. They could not give an explanation of the protective mechanism of
silymarin against MC-LR lethal effects and liver damage. However, they stated that the protection
observed with rifampicin and CyA could be due to the inhibited cellular uptake of MC-LR. These
latter authors also evaluated the protective role of various chemoprotectants (transport inhibitors,
antioxidants, osmotic agents, hepatic activity modulators, etc.) administered as either pretreatment
(1, 3, and 24 h), coadministration, or post-treatment, against toxic effects of MC-LR in mice [33].
Complete protection was observed when rifampicin, CyA, and silymarin were given as pretreatment.
Additionally, rifampicin and CyA exhibited complete protection when coadministered with the toxin;
and only rifampicin was effective at 15 min post-treatment. Despite the higher protective action of
these three transport inhibitors in comparison with the other protective agents assayed, in general, the
studies concerning the use of antioxidant agents are substantially more numerous (see Table 1).
Furthermore, naringin, a grapefruit flavonoid, prevented toxic effects induced by MC-LR, such
as cytoskeletal disruption and apoptotic liver cell death [51], and this protection has been linked
to prevention of MCs uptake in cells [52]. Hence, naringin was able to prevent accumulation of
MC-LR in hepatopancreas of the freshwater snail Sinotaia histrica. Bioaccumulation of MC-LR in
the hepatopancreas of S. histrica is related to the transport mediated by OATPs. Several authors
have proposed three mechanisms of MC toxicity inhibition by naringin in the cell: (1) prevention
of keratin overphosphorylation induced by MCs; (2) inhibition of intestinal absorption of anionic
drugs, such as glibenclamide, via inhibition of OATP-B; and (3) co-incubation with known Oatp/OATP
substrates taurocholate and bromosulfophthalein [17,51,74]. Given that Xie et al. [52] proposed
that OATP mediated MCs uptake into the hepatopancreas of S. histrica, naringin probably directly
inhibited OATP, causing the decrease of MCs concentration in the hepatopancreas. The implication
of OATP transporters in the protective effect of naringin against MCs was further confirmed by
Takumi et al. [53]. Uptake of MC-LR was inhibited by naringin in kidney cells expressing OATP1B3.
This latter mechanism was also observed in nostocyclopeptide-M1 (Ncp-M1), a cyanobacterial cyclic
peptide that inhibits the hepatocyte drug transporters OATP1B3 and OATP1B1 [54]. This substance,
isolated from a culture of Nostoc cyanobacteria strain, did not exhibit toxicity, and, similarly to naringin,
Ncp-M1 has a preference for inhibition of OATP1B3. In addition, the synthetic analogue of Ncp-M1 has
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a specificity for the latter transporter even higher than that of the natural heptapeptide. This finding
is of great importance, not only in the treatment of MCs but also in cancer, because OATP1B3 is also
expressed in some aggressive cancers, where it confers apoptosis resistance.
2.2. Anti-Inflammatory Agents
The toxicosis caused by MCs could also be neutralized by the use of anti-inflammatory agents,
because MCs stimulate the cyclooxygenase pathway of arachidonic acid metabolism in hepatocytes
and macrophages [37]. Consequently, several glucocorticoids (fluocinolone, dexamethasone, and
hydrocortisone) suppressed MC-induced release of free arachidonic acid and release of 6-keto
prostaglandin F1α and thromboxane B2 in rat hepatocytes [75]. It was concluded that glucocorticoid
therapy might be beneficial in MCs toxicosis, although these potential chemoprotectants have not been
extensively studied for this purpose.
Some of the substances that act as transport inhibitors of MCs also exhibited anti-inflammatory
and immunosuppressive activity, such as CyA and rifampicin. In this regard, CyA stimulated
phospholipase activity and inhibited thromboxane synthase activity in macrophages without
interfering with macrophage phagocytic, migratory, or monokine-releasing activity. Nevertheless,
the relationship of these mechanisms of CyA and its ability to prevent MC-LR toxicity was not
clarified [35]. Stoner et al. [43] suggested that CyA protection against MCs might be related to rapid,
transient changes in hepatic macrophage function. Furthermore, Adams et al. [34] reported that
the protection exerted by CyA against MC-LR lethality might be related to immunosuppression.
In addition, the protective effects of CyA and rifampicin on the lethality of MCs were suggested to be
mediated by immunomodulation, inhibition of protein synthesis, blocked cellular uptake of MCs, or a
combination of these effects [36].
2.3. Osmotic Agents
The potential protective efficacy of certain osmotic agents, such as D-glucose, mannitol, and
dihydroxy acetone (DHA), have been assayed against a lethal dose of MC-LR from cultures of
M. aeruginosa (100 µg/kg) in mice [46]. D-glucose at 2 g/kg after 1, 3, and 24 h pretreatment increased
survival time, but no protection from lethality was observed. Likewise, mannitol (2 g/kg) and DHA
(50 mg/kg) had no protective effect at all the pretreatment time points. Pretreatment with mannitol 1 h
prior to administration of MC-LR extended mouse survival time. Both osmotic agents, D-glucose and
mannitol, increased survival time by inactivation or dilution of the toxin in the peritoneal cavity [36].
This preliminary finding is in agreement with the lack of protection provided by mannitol administered
via i.v. against a lethal dose of MC-LR.
2.4. Antioxidants
In this section, various well-known antioxidant substances are reviewed, such as N-acetylcysteine
(NAC), L-cysteine, vitamins (vitamin E, vitamin C), and selenium, with a special focus on their
mechanisms. Moreover, other compounds less widely investigated for this application have also
been considered.
2.4.1. N-Acetylcysteine (NAC)
1. General Aspects
N-acetylcysteine (NAC) is a derivative of cysteine (Cys) which presents an acetyl group in its
nitrogen atom. This compound can be oxidized by many radicals, serving as a nucleophile [76].
However, the presence of the acetyl moiety reduces the reactivity of the thiol as compared with
that of Cys. In comparison to Cys, NAC is not only more water soluble, and less susceptible to
oxidation (and dimerization), but also more tolerable, making it a favorable source of Cys [77,78].
NAC efficiently reduces disulfide bonds in proteins, modifying their structures and affecting their
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ability to bond ligands, competing with larger reducing molecules, and acting as a precursor of Cys for
GSH synthesis [76]. NAC participates in the GSH synthesis route providing the Cys group present in
the GSH molecule [79]. Moreover, NAC enhances the activity of cytosolic enzymes involved in the
GSH cycle. An example of these enzymes is glutathione reductase (GR), which increases the generation
of GSH from GSSG. NAC also protects cells by direct reaction with ROS when GSH levels are depleted.
It is worth mentioning that NAC is not more effective when the concentrations used are higher.
As Halliwell [80] stated, high concentrations of an antioxidant could sometimes lead to pro-oxidant
activity, possibly mediated through a Fenton reaction. Puerto et al. [39] corroborated this in tilapia
(Oreochromis niloticus) exposed to different concentrations of NAC, with the highest one (96.8 mg
NAC/fish/day) presenting pro-oxidant activity.
2. Protective Effects of NAC against MCs
All the features mentioned above make NAC a useful protective agent against substances that may
cause oxidative damage, such as MCs. The efficacy of NAC to prevent or restore MC-induced toxicity
has been investigated in four experimental models (Table 1): in vivo in mice [33] and fish [39,40], and
in vitro in primary rat hepatocytes [38], and in Chinese hamster ovary (CHO) cells [41].
In albino female mice only partial protection from lethality with MC-LR (100 mg/kg) was observed
with 1 h NAC pretreatment (15 mg/kg). With 3 and 24 h pretreatment, although 25% of the animals
survived, coadministration was not effective. L-cysteine at 280 mg/kg offered no protection from
lethality although it extended survival time with 24 h pretreatment [33].
In fish, the protective effects of NAC in vivo against the toxic action of MC-producing
cyanobacterial cells when administered to tilapia (O. niloticus) before MCs exposure have been
demonstrated [39,40] (Table 1). Exposure to a single dose of MC-LR (120 µg MC-LR/fish) resulted
in high levels of LPO in liver and kidney, a high rate of protein oxidation, and a reduction of the
protein content in the liver of the exposed fish. To face this situation, an induction of the activity
of various antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione
peroxidase (GPx), GR, and glutathione S-transferase (GST), was observed [39]. Moreover, MCs
induced morphopathological changes in various organs (liver, kidney, heart, intestine, and gills) [40].
Most of these toxic effects were reverted by pretreatment with NAC for 7 days, as detailed in
Table 2 [39,40,56,61,62]. Treatment with the two lower doses of NAC employed contributed to restoring
oxidative parameters to control levels in liver and kidney. The protection by NAC that was observed
could be due to a direct reaction of its nucleophile center with ROS, and it could act as a Cys supplier for
GSH synthesis [39]. By contrast, in fish only pretreated with the highest dose of NAC, some oxidative
biomarkers were increased, such as LPO, protein oxidation level, and SOD activity in comparison
with the control group [39]. This is in agreement with a previous report by Sevgiler et al. [81], who
demonstrated that high doses of NAC produced superoxide radicals (O2−) and H2O2.
This NAC pretreatment in tilapia prevented, in a dose-dependent manner, histopathological
changes induced by MCs in various organs. The lowest NAC dose (20.0 mg/fish/day) ameliorated
but did not revert the histological alterations induced by MCs, especially glycogenic degeneration in
liver, hemorrhages and hyperemia in kidney, enterocytes with altered microvilli, microhemorrhages
in heart, and hyperemia and desquamations in gill lamellae, which were recovered mainly at the
median dose (44.0 mg/fish/day). One explanation for NAC histopathological prevention may be its
antioxidant activity. By contrast, pathological lesions were observed in all organs in fish exposed only
to the highest dose of 96.8 mg NAC/fish/day [40]. Taking all these results into account, NAC can be
considered a useful chemoprotectant. However, particular attention must be paid to its application
dose because of its own pro-oxidant activity. Similarly, some authors found that NAC exerted its toxic
effects by means of oxidative stress in fish liver at high doses such as intravenous infusion of 550 and
950 mg/kg in 48 h [82], 1 mmol/kg i.p. [83], or 400 mg/kg NAC i.p. [81].
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Table 2. N-acetylcysteine (NAC), Selenium (Se), and Vit E prevention of the effects induced by MCs in tilapia (Oreochromis niloticus), based on the alterations in some
oxidative stress parameters in liver, kidney, and gills. Lipid peroxidation (LPO), protein oxidation, and catalase (CAT), superoxide dismutase (SOD), glutathione
peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST), and GSH/GSSG ratio, together with the histopathological changes in liver, kidney,
heart, intestines, and gills of exposed fish.
Chemoprotectant MCs Dose Parameters Studied
Effects
Ref.
Liver Kidney
NAC
120 µg MC-LR/fish,
oral, 24 h
20, 44, or 96.8 mg/fish/day
(7 days before intoxication) 20 mg 44 mg 96.8 mg 20 mg 44 mg 96.8 mg
[39,40]
LPO Total Total Total Partial Total Alteration
Protein oxidation No prevention No prevention No prevention - - -
CAT Partial Total Total Total Total Total
SOD No prevention No prevention No prevention Total Total No prevention
GR No prevention No prevention No prevention Total Total Alteration
GPx Total No prevention No prevention No prevention No prevention Total
GST Total Total Total No MC effect Alteration Alteration
GSH/GSSG Total Total Total - - -
Histopathology Liver, kidney, heart, intestines, and gills: partial recovery from toxic effects of 20 mg and total from 40 mg.Induction of toxic effect at 96.8 mg.
Se (sodium
selenite)
Cyanobacterial cells
120 µg MC-LR/fish,
oral, 24 h
1.5, 3.0, and 6.0 µg Se/g diet
(7 days before intoxication)
Liver Kidney
[56]
1.5 µg 3.0 µg 6.0 µg 1.5 µg 3.0 µg 6.0 µg
LPO No prevention Partial Total No prevention Alteration Alteration
Protein oxidation Alteration Alteration Alteration Alteration Alteration Alteration
CAT Total Partial No prevention No Se effect Alteration Alteration
SOD No prevention No prevention Total Total Total Total
GR Total Total Total No prevention No prevention No prevention
GPx No prevention Total Total No prevention Partial Total
GST Partial Partial Total No prevention No prevention No prevention
GSH/GSSG Alteration Alteration Alteration - - -
Histopathology
Liver: Partial (1.5 µg) and Total (3.0 and 6.0 µg)
Kidney: No Se effect (1.5 µg), Partial (3.0 µg) and Total (6.0µg)
Heart: Partial (1.5 and 3.0 µg) and Total (6.0 µg)
Intestines: Partial (1.5 and 3.0 µg) and Total (6.0 µg)
Vitamin E
Cyanobacterial cells
120 µg MC-LR/fish,
oral, 24 h
200 or 700 mg vitamin E/kg diet
(7 days before intoxication)
Liver Kidney Gills
[61]
200 mg 700 mg 200 mg 700 mg 200 mg 700 mg
LPO Total Total Partial Total No MC effect No MC effect
Protein oxidation No MC effect No MC effect - - - -
CAT No prevention Total No prevention Total No prevention Total
SOD Total Total Total Total Total Total
GR No MC effect No MC effect PT PT No MC effect No MC effect
GPx Alteration Alteration No prevention No prevention No prevention No prevention
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Table 2. Cont.
Chemoprotectant MCs Dose Parameters Studied
Effects
Ref.
Liver Kidney
Vitamin E
(Trolox)
Cyanobacterial cells
120 µg MC-LR/fish,
oral, 24, 48, or 72 h
700 mg vitamin E/kg diet
(7 days before intoxication)
Liver Kidney Gills
[62]
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h
LPO Partial No prevention No prevention Partial Total Total Partial Partial No prevention
Protein oxidation No prevention No MC effect No MC effect - - - - - -
CAT Partial Partial No MC effect Alteration No prevention No prevention No MC effect Partial No MC effect
SOD Total Partial No prevention No prevention No prevention No prevention No MC effect Total Partial
GPx Partial Partial No prevention Partial No prevention No prevention Partial No MC effect No MC effect
GR Partial Partial No MC effect Partial No MC effect Partial No MC effect No MC effect No MC effect
GST Partial Partial No prevention No prevention No MC effect No prevention No MC effect No MC effect No MC effect
GSH/GSSG Total No MC effect No MC effect No MC effect No MC effect No MC effect No MC effect No MC effect No MC effect
Histopathology
Liver: Partial (24 h) and Total (72 h)
Kidney: Partial (24 h and 72 h)
Heart: Partial (24 h) and Total (72 h)
Intestines: Total (24 h and 72 h)
Gills: Total (24 h and 72 h)
No prevention: no prevention of the alterations is observed; Partial: partial prevention of the alterations is observed; Total: total prevention of the alterations is observed, Alteration:
the chemoprotectant itself induces alteration in intoxicated fish; No MC effect: MCs did not induce any significant alteration in this parameter.
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In vitro, rat hepatocytes exposed to a microcystic cyanobacteria extract and pretreated with NAC
for 6 h significantly enhanced the intracellular GSH level and reduced the cytotoxicity induced by
lactate dehydrogenase (LDH) leakage, as well as cytoskeleton changes [38]. These findings support the
idea that intracellular GSH plays an important role in MCs toxicity. In addition, in CHO cells, NAC
(1–5 nmol/L) has been shown to protect from lesions derived from an oxidative situation and from
apoptosis induced by MC-LR [41]. It maintained the activities of antioxidant enzymes, inhibited LPO,
restrained ROS generation, suppressed caspase-3 activity, and attenuated apoptosis, by improving
mitochondrial function and suppressing oxidative stress.
2.4.2. Selenium (Se)
1. General Aspects
Selenium (Se) is an essential micronutrient for individuals and animals, and it plays a significant
physiological role in the antioxidant defense system [84]. Specifically, Se is a cofactor and structural
component of GPx, which contains four Se atoms, one for each of the subunits that conform the
enzyme [85]. This selenium-dependent enzyme uses GSH as a substrate in the detoxification of
hydroperoxides in extra- and intracellular spaces and of lipid peroxides in cell membranes [86–88], and
it removes the excess of potentially damaging radicals produced during oxidative stress [89,90]. Se can
act both as a nutrient and as a toxicant. Se has been shown to possess potent cytotoxic effects producing
ROS [91]. For this reason, it is important to consider which type of Se (organic or inorganic) should
be considered as an antioxidant, because these cytotoxic effects have been related to the inorganic
form [32].
2. Protective Effects of Se and Derivatives against MCs
Gehringer et al. [59] demonstrated for the first time the protective effects of Se pretreatment in
mice intoxicated with MC-LR, showing a partial recovery from histopathological alterations induced
by MCs, such as hemorrhages, necrotic changes, and apoptosis, as well as a smaller decrease for
glycogen in liver (Table 1). Moreover, they observed a partial recovery of alanine amino transferase
(ALT) levels and a recovery of several oxidative stress biomarkers (LPO), GST activity, and a significant
increase in the activity of GPx, responsible for the protective effects observed.
At present, there is only one study of aquatic organisms that investigates the potential effectiveness
of Se pretreatment in tilapia fish (Oreochromis sp.) exposed to MCs [56] (Tables 1 and 2). Se showed a
dose-dependent protective role depending on the biomarker considered (Table 2). The liver showed
the highest protective effects in comparison to the kidney. Similarly to the study carried out by
Gehringer et al. [59] in mice, GPx activities increased in liver and kidney of non-intoxicated and
Se-supplemented fish. To totally counteract the pathological alterations produced by MCs in kidney,
heart, and intestines, the highest dose (6.0 µg Se/g diet) was required [56]. Moreover, this study
demonstrated the pro-oxidant effects of Se, with increased kidney LPO values in MC-free fish; also,
the highest dose of Se (6 µg/g diet) affected the basal levels of oxidative stress biomarkers (i.e., CAT
activity in kidney, GSH/GSSG ratio in liver) and induced LPO and protein oxidation in non-intoxicated
fish, which is related to the previously described cytotoxic effects of Se [91]. In general, these results
indicated that supplementation with Se can enhance resistance to oxidative stress generated by MCs.
However, the dose of Se should be carefully selected to avoid any potential negative consequence.
The Se trace element κ-selenocarrageenan (Se-Car) is a polysaccharide selenate formed by the
conjugation of Se and carrageenan polysaccharide. This substance, with high biological availability,
has been verified to be safe for animals and humans. Recently, its potential protective effects against
MC-LR-induced hepatotoxicity in mice have been reported [32], this being the only study found in
the scientific literature. Se-Car pretreatment (70 ppb Se) reduced oxidative and histopathological
damage caused by this toxin, and it did not induce adverse effects per se. Se-Car reduced lipid and
protein oxidation, and induced recovery of the antioxidant system (GST, CAT, and SOD) and serum Se
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level. Se-Car pretreatment significantly reduced MC-LR-induced apoptosis and necrosis. Moreover,
Se-Car ameliorated mitochondrial dysfunction by inhibition of specific marker genes. Finally, this
organic compound also alleviated endoplasmic reticulum (ER) stress activation, by reducing the
increase of mRNA expression of eukaryotic translation initiation factor 4E binding protein 1 (eIF4EBP1)
and phosphorylation of eIF2α (p-eIF2α) induced by MC-LR, suggesting that Se-Car could reduce
MC-LR-induced toxicity through ER function restoration. These results suggest that Se-Car could
protect mice from MC-LR intoxication.
2.4.3. Vitamin E
1. General Aspects
Vitamin E has been the most studied chemoprotective agent as a possible treatment against the
toxic effects produced by MCs in various species, including mammals (mice, rats) and aquatic animals
(estuarine crabs, fish). The term vitamin E covers eight related structures (α-, β-, γ-, δ-tocopherols,
and α-, β-, γ-, δ-tocotrienols), all of them amphipathic with a polar chromanol ring and a phytyl
chain; the differences are in the number of methyl groups and their positions in the chromanol
group [92]. Among the four tocopherols and four tocotrienols found in food, only α-tocopherol
meets human vitamin E requirements, and in vivo it is the most abundant and the most bioactive
tocopherol, followed by β-tocopherol, γ-tocopherol, and δ-tocopherol [93,94]. Functionally, vitamin
E represents a first defense against peroxidation of lipids, being the most important lipid-soluble
antioxidant with chain-breaking activity present in the body tissues [95]. The antioxidant power of
vitamin E encompasses the ability to donate H atoms, crossing biological membranes, and the ability
of cytosolic reductants (ascorbate) to recycle tocopheroxyl radical [94]. Moreover, various authors
have proposed that α-tocopherol functions by protecting long-chain polyunsaturated fatty acids, to
maintain them at adequate levels for significant signaling reactions [94]. In general, vitamin E has
long been considered as a cytoprotective factor with suggested roles in preventing inflammatory and
degenerative processes in the liver during exposure to a range of xenobiotics, environmental pollutants,
and dietary factors [96]. Additionally, vitamin E also induces protection against cancer owing to its
antioxidant capacity, and against ischemic heart disease owing to its suppression of the atherosclerosis
process [95].
2. Protective Effects of Vitamin E against MCs
The first study was performed in mice, by a single i.p. injection of 170 or 340 U vitamin E 48 h
before exposure to MC-LR (100 µg/kg), preventing the death of half of the animals employed [36]
(Table 1). However, to determine the effects of vitamin E, most studies have focused mainly on
determining antioxidant parameters. In this regard, a study carried out with mice supplemented with
vitamin E for 4 weeks and treated with i.p. doses of 100 µg/kg MC-LR extract, representing 70% LD50,
and administered every 3 days from day 8, showed a significant decrease in LPO, presumably due to
its free radical-quenching ability, and a partial recovery of GST [59]. Thus, this study differed from the
previous one of Hermansky et al. [36] in the sense that MC-LR was repeatedly given by i.p. injection
and supplementation with vitamin E was given constantly. Vitamin E has also managed to reduce the
oxidative injury to DNA (by formation of 8-hydroxydeoxyguanosine, 8-OH-dG) produced by MC-LR
in mice, and this prevention depended on the concentration of antioxidant employed [63]. Similarly, in
liver of rats orally administered with vitamin E and vitamin C daily for 3 days, significant reductions of
ROS and LPO levels, and a recovery from the changes of ALT and aspartate amino transaminase (AST)
induced by MC-LR were observed [64]. At histopathological level, this study showed that vitamins E
and C produced a decrease of apoptosis and chromatin condensation in hepatocytes and prevented a
reduction in membrane potential, as well as expression of Bax and Bid in MC-LR exposed mice. No
more histopathological studies evaluating the efficacy of vitamin E against MC effects in mammals
are available, as far as we know. In general, in mammals the studies have been performed by the i.p.
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route, an unrealistic exposure scenario. More studies are needed representing a real intake of the toxin
(oral route).
By contrast, in aquatic animals, more organs (liver, kidney, heart, intestine, and gills) have been
studied and more antioxidant parameters have been measured. Moreover, the effects were evaluated
by oral exposure (immersion or diet), more relevant for the aquatic environment. Pinho et al. [60] were
the first authors to evaluate the effect of vitamin E in antioxidant responses in crabs intoxicated with
MC-LR. This study showed that vitamin E pretreatment of intoxicated crabs attenuated the increase
in the activity of GST, compared to animals exposed to the toxin only. Moreover, CAT activity was
reduced in posterior gills only, suggesting that higher concentrations of antioxidants may be needed in
this tissue. Pretreatment also significantly increased nonproteic sulfhydryl groups (NP-SH), reinforcing
the idea that vitamin E was present in gills, and the greater response in posterior rather than in anterior
gills suggested that in the former there might be a higher production of pro-oxidants or perhaps the
antioxidant concentration was starting to be limiting. This may be related to the higher activity of Na+,
K+-ATPase observed in posterior gills of crabs.
Two studies were performed on fish (Tilapia, O. niloticus) exposed to MCs and pretreated with two
different doses of vitamin E. In the first study, Prieto et al. [61] observed that LPO, protein oxidation,
and various enzyme activities (SOD, CAT, GPx, GR) were ameliorated, with the highest vitamin E
dose tested showing the greatest protective effects. The specific protective effects on the biomarkers
assayed as a function of the dose employed, in the liver, kidney, and gills of fish, are shown in Table 2.
Later, these authors also investigated different periods post-exposure to MCs (24, 48, or 72 h) in which
vitamin E (as Trolox, a water-soluble analog of vitamin E) was effective to fight injuries at oxidative
and histological levels in various organs (liver, kidney, intestines, gills, and heart) of tilapia. Trolox was
more effective after 72 h and it helped to restore catarrhal processes with hyperemia, microvilli and
mitochondrial tumefaction, necrotic and enteritis process, and myofibrolysis in the heart. However,
shorter periods were necessary for the recovery of oxidative stress biomarkers. Specifically, LPO values
were recovered in most organs after 24 h, and after 48 h in gills [62] (Table 2). These outcomes suggest
that vitamin E could be used as a preventive measure in MC-exposed fish, which is of great interest to
the aquaculture industry.
The protection offered by vitamin E suggests a potential application for treatment of liver injury
and hepatotoxicity induced by MC-LR. However, some studies show that vitamin E can exhibit
pro-oxidant effects [97], inversely proportional to its antioxidant activity (δ-tocopherol > γ-tocopherol
> α-tocopherol) [98]. For this reason, it is necessary to define the dosages to be used to guarantee
health safety. At present, the studies performed are very scarce and have many limitations, such as
time of exposure, treatment dose, animal species, etc. Further studies are necessary to ensure safe and
effective application of vitamin E in preventing the toxic effects produced by MCs.
2.4.4. Other Antioxidants
Vitamin C is one of the most important water-soluble vitamins, also named L-ascorbic acid.
L-ascorbic acid and dehydroascorbic acid are the major dietary forms of vitamin C. It takes part
in several physiological functions, such as antioxidant activity, immunomodulation, and synthesis
of collagen, carnitine, and neurotransmitters [99,100]. Vitamin C exhibits pro-oxidant activity that
often enhances its cytotoxic effects, including cellular damage through the accumulation of hydrogen
peroxide (H2O2), which leads to the arrest of tumor cell growth and the induction of tumor cell
death [100].
Only one study [63] evaluated the effects of vitamin C per se to reduce the toxicity
of microcystin-induced oxidative DNA damage in vivo in mice in comparison with other
chemoprotectants (vitamin E and melatonin) (Table 1). Although the results suggest the efficacy
of vitamin C, it was lower than that of other compounds. Moreover, another study in mice evaluated
how the toxic effects of MC-LR were ameliorated by vitamin C but in concomitant exposure with
vitamin E [64]. The combined exposure resulted in reduced ROS and LPO levels, and also mitigated
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the apoptosis induced by the mitochondrial damage induced by MC-LR by changing the expression
pattern of proapoptotic proteins. Moreover, the intrahepatic hemorrhages and destruction of the liver
structure induced by MC-LR were totally prevented. These two antioxidant vitamins of low molecular
mass can interact with ROS directly and protect cells and tissues from oxidative stress. Vitamins C and
E may act in a synergistic manner to enhance the antioxidative ability of each other [101–103], so it
could be interesting to study the effects of combinations of various substances in order to reduce the
dose of vitamin E administered.
Melatonin is an amphiphilic molecule and can easily pass through all cellular compartments,
with the highest concentration recorded in mitochondria, potentially protecting them against oxidative
stress [104]. It is suggested that melatonin has protective effects in the heart, liver, kidney, lung,
and testis in rats and in the brain of mice [105]. This endogenous molecule is known to be a potent
antioxidant [106], with anti-apoptotic [107] and anti-inflammatory effects [108]. Melatonin has been
proposed to be the strongest inhibitor of oxidative DNA damage in MC-LR-intoxicated mice in
comparison with vitamin C or vitamin E [63] (Table 1). In fact, it was 60- and 70-fold more effective
than vitamin C or E, respectively. This might be because, firstly, melatonin is a direct free radical
scavenger of the highly toxic •OH, neutralizing two •OH molecules for each melatonin molecule.
Melatonin also scavenges its precursor, H2O2. It has been found that this molecule is mainly located in
the nucleus, possibly contributing to the protective effect against the formation of 8-OH-dG induced
by MCs in mice.
Flavonoids are a diverse family of polyphenolic compounds from plants. They are potent
antioxidants, acting as free radical scavengers, metal chelators, or LPO inhibitors [109]. They also
present anti-inflammatory activity, inhibition of platelet aggregation, antimicrobial and anti-tumor
activities, etc. [110]. Among them, three flavonoids, quercetin, silybin, and morin, have shown different
levels of protection as pretreatment in mice intoxicated with MC-LR (0.75 LD50) [48]. Some hepatic
enzymes (ALT, AST, LDH) were high in a MC-LR treated group, and silybin and morin reversed the
values to control levels at 3 days post-exposure, but no protection was observed 1 day post-exposure.
All three flavonoids reversed the protein phosphatase activity to control levels at both 1 and 3 days
post-exposure. Thus, the protection observed could be due to the combination of their antioxidant
activity, mainly quercetin. Morin prolonged the survival of rat hepatocytes against oxidative damage,
silybin helped to stabilize the plasma membrane of hepatocytes, and all three flavonoids contributed
to conservation of GSH, and inhibitory action on uptake of toxin [48].
Moreover, in recent years there has been increased interest in the potential health benefits of
green tea polyphenols (GTPs), primarily catechins. Among these properties, anti-blood coagulation,
anti-hypertensive activity, oxidative damage repair, HIV treatment, and cancer prevention and
treatment are the most prominent [111,112]. Catechins have a strong antioxidant activity, and
are considered as potent scavengers of ROS [31,113]. In view of the diverse properties of GTPs,
Xu et al. [31] evaluated their chemopreventive efficacy in mice pretreated with GTPs through
intragastric administration at 50, 100, and 200 µg/kg/day (0–18 days) against subacute hepatotoxicity
induced by 10 µg/kg/day MC-LR after 13 days. The results suggested that GTPs caused significant
elevation of GSH levels and SOD activity in serum, as well as decreased hepatic LPO and serum
ALT, AST, and alkaline phosphatase (ALP) activities. Moreover, the pretreatment inhibited hepatic
apoptosis and reduced hepatocellular necrosis. On the basis of this evidence, the hepatoprotective
effect of GTPs may be due to their antioxidant activity, mainly by the functional component of
epigallocatechin-3-gallate (EGCG), and its anti-apoptotic properties [31]. This compound was also
reported to possess anti-inflammatory, antioxidant, and antitumorigenic activities [114]. Several studies
demonstrated that 40 µM MC-LR induced ROS generation, and vascular inflammation via NF-kB in
umbilical vein endothelial cells (HUVECs), and directly stimulated phosphorylation of NF-kB [115].
These authors have subsequently demonstrated that 0–50 µM of EGCG dose-dependently attenuated
MC-LR inhibition of HUVEC viability, migration, and angiogenesis [47]. Furthermore, EGCG inhibited
ROS, TNF-α, and IL-6 expression in MC-LR-stimulated cells in a dose-dependent manner, increasing
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SOD and GSH levels, and reduced nitrite and MDA levels, suggesting that EGCG protected the cells,
at least in part, in an anti-oxidative manner. Moreover, the compound suppressed MC-LR-induced
NF-κB activation, and suppressed MC-LR-induced expression of ICAM-1 and VCAM-1, the most
essential cell adhesion molecules, indicating that EGCG also protected in an anti-inflammatory manner.
All these results suggested that EGCG might be a useful potential candidate for the prevention of
vascular inflammatory processes in MC-LR-induced endothelial cells [47].
Sulforaphane (SFN), a naturally occurring isothiocyanate obtained from cruciferous vegetables
(broccoli, etc.) has been reported as effective in preventing cancer [116], inflammation [117], and skin
damage [118]. The preliminary results found in the literature suggested that SFN has been able to
protect against MC-induced hepatotoxicity in in vitro and in vivo models. Firstly, pretreatment with
10 µM SFN for 12 h protected against MC-LR-induced damage in a variety of cultured cells, such as the
human hepatocellular liver carcinoma HepG2, and the mouse embryonic fibroblast cell line NIH 3T3.
SFN protected against cytotoxicity caused by MC-LR, and this response was mediated through the
nuclear factor erythroid 2-related factor (Nrf2) [57]. Previously, Gan et al. [119] indicated that MC-LR
treatment of HepG2 cells resulted in significant increases in the stability of the Nrf2 transcription factor
in the cytoplasm and its nuclear translocation via binding to the cytosolic regulator protein Keap1.
Thus, MC-LR induced up-regulation of Nrf2 in cancer cells and promoted liver cancer cell growth, and
the results suggested a correlation of this factor with tumorigenesis. The protection induced by SFN
against MC-LR was time-dependent and Nrf2-mediated, resulting in the encoding of proteins such
as phase II enzymes: NAD(P)H quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (OH-1),
associated with antioxidative and anti-inflammatory responses. Moreover, it also raised intracellular
GSH level [57]. To confirm this in vitro study, Sun et al. [58] investigated in vivo the efficacy of the
SFN-induced multi-mechanistic defense system against MC-induced hepatotoxicity in BALB/c mice
injected with 5 µmol of SFN 12 h before injection of 40 or 50 µg/kg MC-LR group. The results
confirmed the protective effect of SFN against MC-LR-induced hepatotoxicity. Moreover, the in vivo
results showed that SFN significantly reduced MC-LR-induced CYP2E1 expression in the liver. In this
regard, SFN is a versatile protective agent because it offers antioxidant activity, and anti-inflammatory
and anti-apoptotic functions. Further preclinical and clinical studies are needed for its safe use as a
potential chemoprotectant against MC-LR hepatotoxicity.
Because it is known that MC exposure can affect the expression of various classes of GST [120],
chemicals that induce expression of these enzymes could be potential chemoprotectants against MC
toxicity. In this regard, lipoic acid (LA) is able to control expression of some genes involved in synthesis
of certain antioxidant enzymes, such as glutamate Cys ligase (GCL) and GST [121,122]. In addition,
it has been reported that LA can act as a radical scavenger, direct antioxidant, chelator of metals,
or regenerator of other antioxidants [123,124]. Amado et al. [49] reported, in a study on carp that
received two i.p. injections (40 mg LA solution/kg) with a 24 h interval between each one, that LA may
play an important role in neuro and liver protection against a toxic dose of 50 µg MC/kg. Results of
GST activity in these organs suggested that LA could be a useful chemoprotectant agent, stimulating
detoxification by increasing GST activity in the brain or by reversion of GST inhibition in the liver.
2.4.5. Comparison of the Effectiveness of the Various Antioxidant Substances in MC-Intoxicated Fish
As described above, several antioxidant substances have been evaluated experimentally to
prevent/counteract MC-mediated effects. However, the differences between these studies (with regard
to the experimental model used, doses/concentrations, etc.) do not allow a systematic comparison.
Consequently, only a comparison between the studies on the protective effects of NAC, Se, and
vitamin E carried out in tilapias exposed to MCs under the same laboratory conditions, using the
same dose and exposure route, is shown in Table 2, in order to clarify which of them might be the
most effective and safe. With regard to the dose required for reversion of the negative effects of MCs,
the antioxidant that needed the lowest dose to induce this effect was Se (1.8 µg/fish) [56], followed
by vitamin E (0.21 mg/fish) [61,62], and NAC (44 mg/fish) [39,40]. However, NAC and Se were
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shown to induce some different anomalies in the redox status of fish when the highest doses were
assayed. In addition, NAC was also shown to induce histopathological alterations per se when a dose
of 96.8 mg/fish was administered [40], which might be related to the pro-oxidant activity described for
NAC in the literature. This makes NAC the least recommended chemoprotectant among these three
substances. Vitamin E has also been reported to present a pro-oxidant effect [97], although no negative
effects were detected with any of the doses used by the authors [61,62], preventing alterations of the
antioxidant biomarkers induced by MCs after 24 h [61]. Moreover, the recoveries of these parameters
were corroborated in another study carried out by these authors, with vitamin E showing its main
effect after 24 h of exposure to MCs versus 48 and 72 h [61]. This highlights the suitability of using
vitamin E for prevention of the negative effects induced by MCs. Therefore, the order of preference and
chemoprotectant dose proposed against MCs-intoxications in fish could be vitamin E (0.21 mg/fish) >
Se (1.8 µg/fish) > NAC (44 mg/fish).
2.5. Diverse Mechanisms
The toxicity of MC-LR may depend on the immune system and may also be caused by cell
membrane alterations. In this regard, lipopolysaccharide (LPS), a characteristic structural component
of Gram-negative bacteria, can also protect against the toxicity of MC-LR in Artemia salina and Daphnia
spp. [50]. In this case, pre-exposure (24 h) to 2 ng/mL of purified cyanobacterial LPS significantly
raised the LC50 of MC-LR in invertebrates. This effect was also found when LPS and MC-LR were
simultaneously administered, but appeared less effective. The decrease in susceptibility may be due
to effects on detoxication enzyme pathways, with changes in GST activities. Moreover, the CYP450
system appeared to be suppressed by LPS.
3. Cylindrospermopsin
Cylindrospermopsin is a tricyclic alkaloid [125] whose main toxicity mechanism is the irreversible
inhibition of protein synthesis [126]. It has been suggested that CYP450 metabolites may be
responsible for the toxicity observed, although CYN metabolites have not been identified so far [15].
Oxidative stress is also involved in CYN toxicity, as it increases intracellular ROS production, reduces
GSH [127], and induced changes in the activity of various oxidative stress biomarkers in vivo and
in vitro [4,128,129]. Liver and kidney have been described as the main target organs of this toxin in vivo.
However, its toxic effects have also been found in other organs, such as heart, stomach, thymus, spleen,
lungs, ovaries, and brain [8,130]. Moreover, in vitro studies carried out in various mammalian cell
lines have reported disruption of cell growth or cytotoxicity [129,131–134]. Furthermore, CYN has
also shown genotoxic activity. Thus, CYN may exert clastogenic and aneugenic activities through
induction of DNA strand breaks. Moreover, CYN upregulated some p-53 genes involved in DNA
damage repair, cell cycle arrest, and apoptosis. Finally, it has been suggested that CYN could present a
tumor-initiating activity in rodents [27].
As in the case of MCs, potential strategies to avoid/mitigate CYN effects are needed. Studies
concerning prevention of cyanotoxin effects are scarce, almost nonexistent in the case of CYN compared
to MCs, and, as far as we know, no studies have been carried out in relation to the use of transport
inhibitors as chemoprotectants against CYN. This is to be expected, as the transport of CYN across
the cell membrane has not been fully elucidated. Several mechanisms have been suggested, such as
passive diffusion [126], facilitated transport mechanism [134], and active transport [135]. Recently,
intestinal absorption of CYN was studied using the Caco-2 human cell line as a model of the intestinal
epithelium [136,137]. In this regard, the first work dealing with this matter reported limited passage
of the toxin through the intestinal epithelium in a time- and concentration-dependent way [136].
Furthermore, the paracellular route has been identified as an important pathway in intestinal CYN
absorption, although a minor carrier-mediated transcellular transport may also be involved [137].
However, the transporters involved in cellular uptake of CYN have not been identified so far.
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Moreover, work regarding protective effects against CYN has been conducted mainly on fish
(O. niloticus) [138–143]. The other studies were carried out on aquatic invertebrates (Artemia salina,
Daphnia magna, and Daphnia galeata), showing cyanobacterial LPS protection against subsequent
exposure to CYN [50], on primary rat hepatocytes, where resveratrol appears to possess a cytoprotective
effect against CYN insult [144], and on rats, in which resveratrol and L-arginine prevented
CYN-induced cardiovascular, liver, and renal changes [145]. Therefore, additional systematic studies
are required, especially in mammals, to establish the effective doses and best administration route
for the various chemoprotectants in order to compare them and make recommendations on their
potential use.
In the case of fish, the chemoprotectants assayed are antioxidants, NAC, Vitamin E, and L-carnitine.
The protective effects of these compounds on CYN intoxication are summarized in Table 3 [138–143],
and the most important aspects are described below.
3.1. Protective Effects of NAC against CYN
The effectiveness of NAC to prevent/reverse CYN-induced toxic effects has only been studied
in fish. Gutiérrez-Praena et al. [138] found that CYN (pure or contained in a lyophilized cell culture)
induced oxidative stress in tilapia (O. niloticus). Firstly, it was demonstrated that NAC pretreatment
per se did not affect any of the oxidative parameters evaluated (LPO, protein oxidation, GSH/GSSG
ratio, and activities of γ-glutamyl cysteine synthetase (γ-GCS), GST, GPx, and gene expression of GST
and GPx) in fish that were not exposed to the toxin, indicating that this agent only ameliorates or
prevents CYN-induced toxic effects, with the exception of GST and GPx gene expression. In liver and
kidney, NAC improved the toxic effects induced by CYN (pure or from a cyanobacterium extract), and
both doses were effective in preventing CYN-induced oxidative stress, although, in general, the highest
dose induced a greater protective effect. As previously stated, NAC improved the redox situation, as it
was able to recover γ-GCS activity and hence GSH levels [81], and react directly with ROS and some
radicals (such as •OH, •NO2, CO3•−, HNO, and HOCl, at physiological pH). It has also been shown
that NAC plays a role in gene expression of some enzymes, GST and GPx in this case [146,147]. Finally,
as Gutiérrez-Praena et al. [138] pointed out, the different responses of NAC in liver and kidney could
be due to kinetic differences in the two organs.
Similarly, Gutiérrez-Praena et al. [139] evaluated recovery from the histopathological changes
induced by CYN in various organs of tilapia (O. niloticus) after pretreatment with NAC (Table 3).
Both doses of NAC were able to impede the negative effects of CYN in the liver (steatosis and presence
of glycogen), with the 45 mg/kg/day dose being the more effective. Similarly, with regard to the
heart, only the dose of 45 mg/kg/day NAC was able to avoid the negative effects produced by CYN
(myofibrolysis, edema, and hemorrhages). Kidney (glomerular atrophy, dilatation of the Bowman’s
capsule, and thickening of basal membranes), GI tract, and gills were totally protected by the lower
dose of 22 mg/kg/day. Globally, it can be assumed that NAC pretreatment appeared to prevent the
lesions induced by CYN in a dose-dependent way. These results were also corroborated by the same
authors by immunohistochemistry, a technique using CYN antibodies to detect CYN in the cells of
the various organs studied. Thus, it was observable that pretreatment with NAC reduced partially
(22 mg/kg/day) or totally (45 mg/kg/day) the presence of CYN in the cells of the various organs.
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Table 3. Effects of N-acetylcysteine, L-carnitine, and vitamin E supplementation on the changes induced by cylindrospermopsin (CYN) in some oxidative stress
parameters in liver and kidney of tilapia fish (O. niloticus): lipid peroxidation (LPO), protein and DNA oxidation, activities of NADPH oxidase, glutathione-S-transferase
(GST), glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase (CAT), γ-glutamyl-cysteine synthetase (γ-GCS), GSH/GSSG ratio, GST and GPx gene
expression, together with the histopathological and morphometric changes in liver, kidney, heart, GI tract, and gills of exposed fish.
Chemoprotectant CYN Dose Parameters Studied Effects References
NAC
200 µg/kg bw
(pure and from an
extract of
A. ovalisporum)
22, 45 (mg/fish/day) 7 days Liver Kidney
[138,139]
22 45 22 45
LPO Total Total Partial Partial
Protein oxidation No CYN effect No CYN effect Total Total
GST Total Total No CYN effect No CYN effect
GPx Total Total No CYN effect No CYN effect
γ-GCS Partial Partial Total Total
GSH/GSSG Total Total Total Total
GST gene expression Increased Increased Reduced Reduced
GPx gene expression Increased Increased - -
Histopathology
Liver and heart: partial prevention at 22 mg/fish/day, and total prevention at
45 mg/fish/day
Kidney, GI tract, and gills: total prevention at 22 mg/fish/day
LC
400 µg/kg bw
(pure and from an
extract of
A. ovalisporum)
20, 40 (mg/fish/day) 21 days Liver Kidney
[140,143]
20 44 20 44
LPO Total Total Total Total
Protein oxidation Total Total Total Total
DNA oxidation Total Total Total Total
NADPH oxidase Total Total No CYN effect No CYN effect
GST No CYN effect No CYN effect Total Total
GPx No prevention No prevention No CYN effect No effect CYN
SOD No CYN effect No CYN effect Partial Partial
CAT No CYN effect No CYN effect Total Total
γ-GCS No CYN effect No CYN effect Total Total
GSH/GSSG Total Total Total Total
Histopathology Liver, kidney, GI tract, and gills: total prevention at 20 mg/fish/day
Heart: no prevention at 20 mg/fish/day, and total prevention at 44 mg/fish/day
Morphometry Liver and heart: No CYN effect
Kidney: total prevention at 20 mg/fish/day
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Table 3. Cont.
Chemoprotectant CYN Dose Parameters Studied Effects References
Vitamin E
400 µg/kg bw
(pure)
25 (mg/fish/day) 7 days Liver Kidney
[141,142]
25 25
LPO Total Total
Protein oxidation Total No CYN effect
DNA oxidation No CYN effect No CYN effect
GST Total Total
GPx Total No CYN effect
SOD Total No prevention
CAT Total Total
γ-GCS Total No CYN effect
GSH/GSSG Total No CYN effect
Histopathology Liver, kidney, GI tract, gills, and brain: total prevention
Heart: partial prevention
Morphometry Liver, kidney, and heart: total prevention
No prevention: no prevention of the alterations is observed; No CYN effect: CYN did not induce any significant alteration in this parameter; Partial: partial prevention of the alterations is
observed; Total: total prevention of the alterations is observed.
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3.2. L-carnitine
3.2.1. General Aspects
L-carnitine (β-hydroxy-γ-N-trimethyl ammonium-butyrate; LC) is a quaternary amine soluble in
water, formed by lysine and methionine, with participation of vitamin C, among other compounds
produced in animal tissues [148]. It is the biologically active stereoisomer of carnitine [149]. It plays
an important function in fatty acid metabolism, by facilitating the mitochondrial membrane crossing
of long-chain fatty acids for their β-oxidation, and energy metabolism, mainly in skeletal and
heart muscles [150,151]. In humans, there is increasing evidence of the beneficial effects of LC
supplementation in obesity, diabetes, and endocrine disorders [149,152].
The effect of LC supplementation on lipids (triglycerides, high-density lipoprotein-cholesterol,
and apolipoprotein-A1) may be explained by its antioxidant potential [153]. Several works have shown
that LC is also a good antioxidant [140,154–156]. LC seems to impede ROS formation, by chelating
ferrous ions, managing to stabilize the free radicals formed on the α-carbon [157]. LC appears to exhibit
its antioxidant effects also on the non-enzymatic defense system (GSH) apart from the enzymatic one,
and probably protects from this damage by scavenging of free radicals, reducing LPO, maintaining
GSH levels [158,159], and preventing alterations in various biomarkers of oxidative stress in fish tissues
(liver and kidney) [140].
The heart is one of the most affected organs in LC or acetyl-L-carnitine (ALC) carrier (CAC)
deficiency, as this is the main source of energy in this organ. CAC allows the fatty acyl moieties
to be transported into the mitochondria for its β-oxidation by catalyzing the LC or ALC exchange.
Consequently, several cardiovascular diseases arise from CAC deficiency [160], and it has been
suggested that they could be ameliorated by supplementation with LC [159]. Although the
mechanism(s) by which LC exerts its preventive effects in some disorders are not well defined, it seems
that they are due to the recovery of normal oxidative status and myocardial energy reserves [161].
The kidney plays an important role in the metabolism of LC (it reabsorbs more than 95% of filtered
LC, apart from participating in LC synthesis). LC prevented hypertension-associated renal function
damage by reversion of the alterations induced in the activities, protein, and gene expressions of
the antioxidant enzymes GPx, GR, and SOD [162]. It also produced up-regulation of eNOS (the
enzyme responsible for nitric oxide production), and down-regulation of the renin–angiotensin system
(RAS) components and NADPH oxidase subunits NOX2 and NOX4 [163]. LC seemed to improve
the oxidative stress response through a specific modulation of nuclear transcription factors kappa B
(NF-κB), Nrf2, and peroxisome proliferator-activated receptor alpha (PPARα). Therefore, inhibition of
NADPH oxidase led to less production of superoxide anions, which may increase the expression of
Nrf2 and PPARα and decrease that of NF-κB, thus enhancing the antioxidant defense systems [162].
In this regard, LC anti-inflammatory properties have also been reported by inhibition of the NF-κB
pathway by suppression of ROS formation [164,165]. In general, it has been demonstrated that
up-regulation of Nrf2 mRNA expression is associated with increases in antioxidant genes [166].
Thus, LC increased the activity of γ-GCS and CuZn-SOD by activation of the Nrf2—antioxidant
responsive element (Nrf2-ARE) [159]. This element helps to maintain intracellular redox homeostasis
in mammals [167]. Moreover, LC protects mitochondria against fatty acid stress and apoptosis
induction through inhibition of mitochondrial swelling and Cyt-c release [168].
LC has been used for its beneficial effects on the growth of fish and crustaceans, as well as
for feed conversion in several aquatic species [169–171]. It can promote growth performance by a
protein-sparing effect, protect fish against high levels of xenobiotics and ammonia, and alleviate stress
due to extreme changes in water temperature [151].
According to the literature reviewed, LC and its esters may be administered before, together with,
or after the toxicant/injury, from minutes and hours to various weeks afterwards, depending on the
experimental model. Harpaz [151] showed that dietary supplementation of fish with LC (100–4000 mg
LC/kg of diet) administered for long periods (such as 120 days) managed to exert protection during
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exposure to xenobiotics. In tilapia fish, LC supplementation with 900 mg LC/kg diet was effective with
regard to their growth and reproductive performance [172]. Other authors, however, while observing
that LC treatments offered better resistance to xenobiotics, showed that it had no effect on growth or
survival of tilapia [173]. However, Liu et al. [174] observed some alterations in liver and kidney of rats
that may provide the caution information for the safety of supplementation with LC for long periods
(8 weeks).
3.2.2. Protective Effects of L-carnitine against CYN
Guzmán-Guillén et al. [140,143] demonstrated the usefulness of LC dietary pretreatment for the
first time with 400 or 880 mg LC/kg bw (corresponding to 20 or 44 mg LC/fish/day), for 21 days,
as prophylaxis for the oxidative stress and histopathological harm caused in tilapia fish (O. niloticus)
by acute exposure to an extract of CYN from lyophilized A. ovalisporum cells or pure CYN (400 µg
CYN/kg bw) (Table 3). LC supplementation per se did not result in any toxic effect in fish not
exposed to CYN, only ameliorating or preventing the effects of the toxin. As can be seen in Table 3,
both doses of LC gave total protection, fighting most of the CYN-induced alterations, with a few
exceptions: no prevention of GPx activity in liver, partial prevention of increased SOD activity in
kidney. Apart from this, the lack of CYN effect on some parameters in liver or kidney of intoxicated
fish made it impossible to evaluate the protective effects of LC in those cases. Supplementation
with LC seemed to prevent CYN-induced alterations partly because of the reasons explained above:
its function in β-oxidation, counteracting ROS and metal-chelating properties, anti-ischemic action,
together with its anti-inflammatory effects or its ability to increase intracellular carnitine content,
improving mitochondrial oxidative phosphorylation and production of energy [175,176].
More recently, these antioxidant properties of LC also protected from the histopathological lesions
caused by CYN under the same conditions as in the oxidative stress assay [143]. The lower dose of
20 mg LC/fish/day, managed to prevent completely the histological damage produced by CYN in liver,
kidney, intestines, and gills, as well as morphometric damage in the proximal and distal convoluted
tubules (PCT and DCT) in the kidney. However, it is noteworthy that the highest dose tested of LC
(44 mg LC/fish/day) was needed to completely protect the heart from the histopathological injuries
(hemorrhages) caused by CYN. A hypothesis for the heart damage prevention is that LC may have
impeded the decrease found in ATP caused by CYN, by restoring the myocardium with a good content
of carnitine, together with its role in fatty acid β-oxidation. This could be due to the role of LC in
metabolic disorders and energy metabolism in tissues that obtain a great deal of their energy from
β-oxidation, such as liver, skeletal muscle, heart, and placenta [177]. Another theory is based on the
ability of LC to increase production of NO [178] and to restore myocardial energy reserves [179], which
could prevent cardiac interstitial edema. The role of carnitine in the gastrointestinal tract is still under
discussion, and it seems that the facility of LC in fatty acid oxidation could be mandatory to maintain
the normal morphology and function of this organ in mice [177]. The mechanisms for LC protection in
gills may probably be explained because it can interact with cardiolipin, protecting membranes and
enhancing the impermeability of epithelial layers in the gills, by stimulation of energy metabolism.
L-carnitine supplementation presents some advantages compared to previous antioxidants tested
for prevention of the effects produced by cyanotoxins (for details see Section 3.4). The lowest dose
tested for LC (20 mg LC/fish/day) was normally enough for prevention of the histopathological
injuries produced by CYN in most organs, with the exception of the heart [143]. In addition, LC
managed to prevent the toxic effects of double the CYN dose (400 µg CYN/kg bw) tested in the work
of Gutiérrez-Praena et al. [139] (200 µg CYN/kg bw). Moreover, carnitine is a natural compound, free
from toxicity even when several grams are administered orally, as it is readily excreted. Nevertheless,
despite this and the findings regarding the beneficial effects of LC against CYN insult, as well as in
several disorders, care should be taken in cases of long-term LC supplementation, as there is evidence
of rat liver and kidney impairment after supplementation with LC for long periods [174]. If doses are
Toxins 2017, 9, 175 25 of 36
not a concern, an issue to consider would be the cost it would represent. In this regard, the application
of high levels of LC may not be very cost-effective [151].
3.3. Protective Effects of Vitamin E against CYN
Taking into account the protection offered by Trolox (vitamin E) in MC intoxications,
Guzmán-Guillén et al. [8] were pioneers in evaluating the protection offered by this chemoprotectant
(700 mg vitamin E/kg bw/day, or 25 mg/fish/day, for 7 days) on the effects produced in liver and
kidney of tilapia by acute exposure to CYN (Tables 1 and 3). Changes induced in almost every oxidative
stress biomarker were prevented by vitamin E supplementation in both organs studied, except in
SOD activity, which was not prevented in kidney of pretreated, intoxicated fish (Table 3). Again, no
changes were detectable for some parameters after CYN exposure, so the effect of the chemoprotectant
could not be demonstrated in those cases. Vitamin E per se did not induce any significant changes in
this enzymatic activity. The prevention of CYN-induced increase in LPO is in accordance with other
antioxidants with similar doses: 22 mg NAC or 20 mg LC/fish/day [138,140]. This protection may
easily be attributed to the protection of membranes from oxidative harm, as vitamin E can scavenge
lipid peroxyl radicals that would create lipid peroxidation. In this way, vitamin E can prevent ROS
from reacting with vital macromolecules (lipids, proteins, and DNA). Vitamin E showed its favorable
effect in counteracting impairment in GST and GPx activities in liver and kidney, or in liver of exposed
fish, respectively. Moreover, vitamin E per se did not alter GPx enzymatic activity [138]. In the kidney,
vitamin E did not manage to restore SOD activity, though a slight enzymatic increase was observed in
fish pretreated with the antioxidant, indicating that it can improve the antioxidant condition in kidney
of exposed fish. Vitamin E counteracts ROS by scavenging, which could explain the increased GSH
levels, similarly to LC, which increases γ-GCS and GSH in liver and kidney of intoxicated fish from 20
mg LC/fish/day [140]. Thus, supplementation with a non-enzymatic component of the antioxidant
defense system, such as vitamin E, seemed to help to protect against the oxidative stress induced by
CYN by two pathways: by itself and by reinforcing the enzymatic antioxidant defense system, which
constitutes the first line of defense against oxidative damage. The liver is considered to be the most
important organ involved in the regulation of redox metabolism; it is one of the main targets of CYN
and the protective effects of vitamin E have been mainly visible in this organ. Other authors previously
noted in connection with MCs and vitamin E that for better protection the chemoprotectant needed
to be administered as a preventive measure before exposure to MCs, rather than as a treatment after
intoxication [55,59].
With regard to prevention of CYN-induced histopathological lesions [142], the dose of 25 mg
vitamin E/fish/day (similar to the lowest one employed for NAC and LC), totally prevented damage in
liver, kidney, intestines, and gills. A partial but still quite evident prevention by vitamin E was detected
in the heart, avoiding the myofibrolysis and reducing the presence of edema. This demonstrates a
slightly higher potency of vitamin E to prevent heart injuries compared to LC, because at these doses
LC was still not able to protect heart structures completely. Apart from the organs protected by NAC
and LC, it was suggested for the first time that vitamin E managed to prevent the neurotoxic injuries
caused by CYN in fish brains. It is important to maintain brain structures, as it functions as a center of
all functions and any alteration suffered there may have fatal consequences. In this regard, vitamin E
is the only chemoprotectant that could exert neuroprotective effects in CYN-exposed fish, preventing
the structural lesions that might be caused by the functional ones. Morphologically, supplementation
with vitamin E prevented CYN-induced increases in hepatocyte nuclear diameters, PCT and DCT
diameters, and capillary diameters in kidney, as well as decreases in cardiac fiber diameters.
3.4. Global Comparison of Antioxidant Effectiveness in CYN-Intoxicated Fish
Pretreatment of fish with vitamin E demonstrated several advantages over other antioxidants,
such as NAC or LC. For example, a NAC dose (22 mg NAC/fish) similar to that of vitamin E (25 mg
vitamin E/fish) and LC (20 mg LC/fish) protected against 200 µg pure CYN/kg bw, whereas vitamin
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E and LC were able to exert this effect against twice the CYN dose (400 µg pure CYN/kg bw),
demonstrating greater efficacy. Moreover, it appears that for recovery of protein oxidation and GST
activity greater NAC doses (45 mg/fish/day) are needed. In fact, this dose was still not enough in
some cases, as γ-GCS activity decreased in liver of fish [138]. Moreover, vitamin E per se did not
induce any significant changes in GPx activity, whereas pretreatment with 45 mg NAC/fish/day in
fish intoxicated with lyophilized cells induced GPx activity [138]. Earlier works have also documented
NAC pro-oxidant effects [40,138], which remains behind vitamin E and LC for the selection of the
best option. Although the pro-oxidant activity of vitamin E at high doses has been demonstrated
in vivo [180], supplementation of CYN-intoxicated fish with 25 mg vitamin E/fish did not show
this behavior per se [140–142]. Furthermore, in general, NAC offered only partial protection against
histopathological changes induced by CYN (or MCs), normally needing the highest dose (45 mg
NAC/fish/day) for total prevention [40,139].
No pro-oxidant effects were shown as a result of administration of LC by itself, which is an
advantage. However, prevention of some oxidative stress biomarkers was better with vitamin E than
with LC. As with NAC, in some cases the highest dose of 40 mg LC/fish/day was needed for total
protection from some alterations, such as GST, GPx, and SOD activities in the liver, whereas the dose
of vitamin E required to achieve it was lower. In any case, vitamin E showed total protection against
practically all alterations found in oxidative stress biomarkers in the liver and almost all in the kidney,
with the exception of SOD activity in kidney. The achievements of vitamin E regarding the prevention
of morphometric alterations is similar but more complete compared to LC, as this chemoprotectant
was only effective in the case of the kidney, and the toxin did not induce any of these alterations in
liver and heart of fish in that experiment [143].
Therefore, taking into account the effective doses, costs, and possible side effects under
the conditions assayed in the studies reviewed, the order of preference proposed for the use of
chemoprotectants against CYN-intoxications in fish would be: vitamin E > LC > NAC. It is worth
mentioning that this is the recommendation at the assayed doses because vitamin E has been shown
to exert pro-oxidant effects at high levels of supplementation. In addition, there is a need to study
prevention of damage in fish by exposure to specific combinations of cyanotoxins. Taking into account
the neurotoxic effects of CYN [8] and the effectiveness of LC in ameliorating brain injuries [181],
another issue for future studies could be the neuroprotection offered by LC against CYN exposure
in fish, and comparison of antioxidants. For this purpose, previous studies demonstrated that using
short-chain esters of LC such as ALC is recommended over free LC or its long-chain esters such as
propionyl-L-carnitine (PLC), because of better crossing of the blood-brain barrier [181].
4. Conclusions
The potential efficacy of various chemoprotectants to prevent or mitigate the toxic effects induced
by cyanobacterial toxins has been reviewed, particularly in relation to MC intoxications. Among the
different types of compounds evaluated, antioxidant substances are the most frequently studied, with
vitamin E being the one with the best profile. Available data are limited, therefore more systematic
research would be necessary to define effective doses, times of exposure, and administration route for
the various protective substances and cyanotoxins, depending on the species to be protected. Moreover,
more realistic scenarios including exposure to cyanobacterial toxin mixtures should be considered, as
well as the concomitant use of various chemoprotectants to take advantage of their potential synergistic
effects. In addition, it would be of interest to elucidate the molecular mechanisms involved and the
influence of these substances on other biomarkers not extensively investigated (i.e., neurotoxicity,
immunotoxicity, etc.). Finally, further investigation would be required to extrapolate the published
results to a human exposure scenario.
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